JP2011504460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504460A5 JP2011504460A5 JP2010530101A JP2010530101A JP2011504460A5 JP 2011504460 A5 JP2011504460 A5 JP 2011504460A5 JP 2010530101 A JP2010530101 A JP 2010530101A JP 2010530101 A JP2010530101 A JP 2010530101A JP 2011504460 A5 JP2011504460 A5 JP 2011504460A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tenb2
- drug conjugate
- conjugate compound
- cysteine engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018417 cysteine Nutrition 0.000 claims description 62
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 62
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 60
- 239000000611 antibody drug conjugate Substances 0.000 claims description 59
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 24
- 210000004881 tumor cell Anatomy 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 125000005647 linker group Chemical group 0.000 claims description 15
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims description 12
- 102100026160 Tomoregulin-2 Human genes 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- -1 free cysteine amino acids Chemical class 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 108010044540 auristatin Proteins 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 102100031013 Transgelin Human genes 0.000 claims description 4
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 235000013477 citrulline Nutrition 0.000 claims description 4
- 229960002173 citrulline Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 4
- 235000008191 folinic acid Nutrition 0.000 claims description 4
- 239000011672 folinic acid Substances 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- 229960003881 letrozole Drugs 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- 229960001691 leucovorin Drugs 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 229960002087 pertuzumab Drugs 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 2
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 claims description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 claims description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 230000000536 complexating effect Effects 0.000 claims description 2
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- 235000020960 dehydroascorbic acid Nutrition 0.000 claims description 2
- 239000011615 dehydroascorbic acid Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- AMKBTTRWLGVRER-OFVILXPXSA-N n-[(2s)-1-[[(2s)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(CO)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O AMKBTTRWLGVRER-OFVILXPXSA-N 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98141107P | 2007-10-19 | 2007-10-19 | |
| US60/981,411 | 2007-10-19 | ||
| PCT/US2008/080102 WO2009052249A1 (en) | 2007-10-19 | 2008-10-16 | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013095417A Division JP2013173776A (ja) | 2007-10-19 | 2013-04-30 | システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504460A JP2011504460A (ja) | 2011-02-10 |
| JP2011504460A5 true JP2011504460A5 (enExample) | 2011-10-13 |
| JP5606916B2 JP5606916B2 (ja) | 2014-10-15 |
Family
ID=40242684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530101A Expired - Fee Related JP5606916B2 (ja) | 2007-10-19 | 2008-10-16 | システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体 |
| JP2013095417A Withdrawn JP2013173776A (ja) | 2007-10-19 | 2013-04-30 | システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013095417A Withdrawn JP2013173776A (ja) | 2007-10-19 | 2013-04-30 | システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8937161B2 (enExample) |
| EP (1) | EP2209808B1 (enExample) |
| JP (2) | JP5606916B2 (enExample) |
| KR (1) | KR101622412B1 (enExample) |
| CN (1) | CN101835803B (enExample) |
| AR (1) | AR068941A1 (enExample) |
| AU (2) | AU2008312457B2 (enExample) |
| BR (1) | BRPI0818780A2 (enExample) |
| CA (1) | CA2698541C (enExample) |
| CL (1) | CL2008003074A1 (enExample) |
| CO (1) | CO6390071A2 (enExample) |
| ES (1) | ES2450755T3 (enExample) |
| IL (1) | IL204159A (enExample) |
| MX (1) | MX2010003718A (enExample) |
| MY (1) | MY188455A (enExample) |
| NZ (1) | NZ584514A (enExample) |
| PE (2) | PE20140833A1 (enExample) |
| RU (1) | RU2505544C2 (enExample) |
| TW (1) | TWI438004B (enExample) |
| WO (1) | WO2009052249A1 (enExample) |
| ZA (1) | ZA201001383B (enExample) |
Families Citing this family (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| US8937161B2 (en) | 2007-10-19 | 2015-01-20 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| US20110020323A1 (en) | 2009-07-15 | 2011-01-27 | Tim Beaumont | Gram-positive bacteria specific binding compounds |
| CN102770456B (zh) * | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| WO2011082187A1 (en) | 2009-12-30 | 2011-07-07 | Genentech, Inc. | Methods for modulating a pdgf-aa mediated biological response |
| EP2554669B1 (en) | 2010-03-26 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Novel antibody having modification site introduced therein, and antibody fragment |
| RS52983B (sr) | 2010-04-15 | 2014-02-28 | Spirogen Sárl | Pirolobenzodiazepini i njihovi konjugati |
| CN119552249A (zh) * | 2010-06-08 | 2025-03-04 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| MX2013014583A (es) | 2011-06-10 | 2014-03-31 | Mersana Therapeutics Inc | Conjugados de proteina-polimero-farmaco. |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| HUE025661T2 (en) | 2011-10-14 | 2016-04-28 | Medimmune Ltd | Pyrrolobenzodiazepines and their conjugates |
| US20150030602A1 (en) * | 2011-12-23 | 2015-01-29 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
| US9814782B2 (en) * | 2012-02-24 | 2017-11-14 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
| EP2638916A1 (en) * | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
| NZ629283A (en) * | 2012-03-16 | 2016-04-29 | Covagen Ag | Novel binding molecules with antitumoral activity |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| KR102006997B1 (ko) * | 2012-07-03 | 2019-08-02 | 한국생명공학연구원 | ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자 |
| EP2890402B1 (en) | 2012-08-31 | 2019-04-17 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| SI2766048T1 (sl) | 2012-10-12 | 2015-03-31 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| CA2887895C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd19 antibody conjugates |
| JP6367204B2 (ja) | 2012-10-12 | 2018-08-01 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 結合用のピロロベンゾジアゼピン誘導体の合成および中間体 |
| TR201808051T4 (tr) | 2012-10-12 | 2018-06-21 | Adc Therapeutics Sa | Pirrolobenzodiazepin antikor konjugatları. |
| HUE041274T2 (hu) | 2012-10-12 | 2019-05-28 | Adc Therapeutics Sa | Pirrolobenzodiazepin-anti-PSMA-antitest konjugátumok |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| CN105102004B (zh) | 2012-10-12 | 2019-01-25 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓-抗cd22抗体结合物 |
| LT2906248T (lt) | 2012-10-12 | 2019-02-11 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
| CN110452242A (zh) | 2012-12-21 | 2019-11-15 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| CA2894959C (en) | 2012-12-21 | 2022-01-11 | Spirogen Sarl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| WO2014106208A1 (en) * | 2012-12-28 | 2014-07-03 | Blend Therapeutics, Inc. | Targeted conjugates encapsulated in particles and formulations thereof |
| CN103933575B (zh) | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| WO2014124316A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| ME03394B (me) | 2013-02-22 | 2020-01-20 | Medimmune Ltd | Antidllз-antitelo-pbd konjugati i nihovа upotreba |
| IL319584A (en) | 2013-03-11 | 2025-05-01 | Genzyme Corp | Polypeptides with hyperglycosidic bonds |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| MX363787B (es) | 2013-03-13 | 2019-04-03 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de los mismos. |
| ES2731779T3 (es) | 2013-03-13 | 2019-11-19 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| MA38567A1 (fr) * | 2013-04-16 | 2017-09-29 | Genentech Inc | Variantes de pertuzumab et leur évaluation |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| HUE050451T2 (hu) | 2013-05-31 | 2020-12-28 | Genentech Inc | Anti-fal-teichonsav antitestek és konjugátumok |
| US9884126B2 (en) | 2013-05-31 | 2018-02-06 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| EP3018143B1 (en) | 2013-07-03 | 2019-05-29 | Seoul National University R&DB Foundation | Chicken antibody transformed into cysteine and site-specific conjugation using same |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| AU2014307080B2 (en) | 2013-08-12 | 2018-06-07 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
| JP6463361B2 (ja) | 2013-09-08 | 2019-01-30 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| DK3054992T3 (da) | 2013-10-11 | 2019-10-28 | Asana Biosciences Llc | Protein-polymer-lægemiddelkonjugater |
| WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| CN105828840B (zh) | 2013-12-16 | 2020-08-04 | 基因泰克公司 | 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法 |
| EA201691023A1 (ru) | 2013-12-16 | 2016-10-31 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством |
| EA201691683A1 (ru) | 2014-02-21 | 2017-04-28 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме |
| CN104672330A (zh) * | 2014-03-11 | 2015-06-03 | 南京任诺药业有限公司 | 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-N267C |
| CN104788566A (zh) * | 2014-03-11 | 2015-07-22 | 南京任诺药业有限公司 | 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-V280C |
| CN116333148A (zh) | 2014-03-19 | 2023-06-27 | 建新公司 | 靶向模块的位点特异性糖工程化 |
| CA3194672A1 (en) | 2014-04-10 | 2015-10-15 | Af Chemicals, Llc | Affinity medicant conjugates |
| US10285955B2 (en) | 2014-04-10 | 2019-05-14 | Af Chemicals, Llc | Affinity medicant conjugate |
| US11135182B2 (en) | 2014-04-10 | 2021-10-05 | Af Chemicals, Llc | Affinity medicant conjugates |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
| BR112016024619A2 (pt) | 2014-04-25 | 2017-10-10 | Pf Medicament | conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer |
| HRP20192254T1 (hr) | 2014-04-25 | 2020-03-06 | Pierre Fabre Medicament | Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma |
| US10202458B2 (en) | 2014-04-25 | 2019-02-12 | Pierre Fabre Medicament | IGF-1R antibody and its use as addressing vehicle for the treatment of cancer |
| US10273208B2 (en) * | 2014-05-23 | 2019-04-30 | Northwestern University | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| EP3191134B1 (en) | 2014-09-12 | 2019-11-20 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CA2957148A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
| WO2016044560A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| PT3204425T (pt) | 2014-10-09 | 2020-12-18 | Genzyme Corp | Conjugados anticorpo fármaco glicomanipulados |
| KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| JP6751393B2 (ja) | 2014-12-03 | 2020-09-02 | ジェネンテック， インコーポレイテッド | 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用 |
| CN107206101B (zh) | 2014-12-03 | 2021-06-25 | 基因泰克公司 | 季铵化合物及其抗体-药物缀合物 |
| JP6742314B2 (ja) | 2014-12-03 | 2020-08-19 | ジェネンテック， インコーポレイテッド | 抗黄色ブドウ球菌抗体リファマイシン複合体及びその使用 |
| EP3280806A4 (en) | 2015-04-10 | 2018-12-05 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| ES2854298T3 (es) * | 2015-09-22 | 2021-09-21 | Byondis Bv | Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1 |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| US9669106B2 (en) | 2015-10-26 | 2017-06-06 | Pierre Fabre Medicament | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer |
| AU2016344663B2 (en) | 2015-10-26 | 2023-09-07 | Pierre Fabre Medicament | Composition for the treatment of IGF-1R expressing cancer |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107847605B (zh) | 2015-11-25 | 2021-12-24 | 乐高化学生物科学股份有限公司 | 包含分支接头的抗体-药物缀合物及其相关方法 |
| CA2949032A1 (en) | 2015-11-30 | 2017-05-30 | Pfizer Inc. | Site specific her2 antibody drug conjugates |
| UA124622C2 (uk) * | 2015-12-18 | 2021-10-20 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Кон'юговані імуноглобуліни з c-кінцевим лізином |
| NZ744185A (en) | 2015-12-30 | 2025-09-26 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| MX2018009085A (es) | 2016-01-27 | 2019-05-09 | Sutro Biopharma Inc | Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74. |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| PT3423105T (pt) * | 2016-03-02 | 2021-07-19 | Eisai R&D Man Co Ltd | Conjugados de anticorpo-fármaco à base de eribulina e métodos de utilização |
| SG11201807537RA (en) | 2016-03-04 | 2018-09-27 | Genentech Inc | Process for the preparation of an antibody-rifamycin conjugate |
| US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック， インコーポレイテッド | Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法 |
| WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
| JP2019530434A (ja) | 2016-08-05 | 2019-10-24 | ジェネンテック， インコーポレイテッド | アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法 |
| CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
| CN107789630A (zh) * | 2016-10-08 | 2018-03-13 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体‑毒素偶联物及其制备方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CA3047686C (en) | 2017-02-08 | 2020-07-07 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3544636B1 (en) | 2017-02-08 | 2021-03-31 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| JP7664680B2 (ja) | 2017-03-29 | 2025-04-18 | リガケム バイオサイエンシズ， インク． | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| JP2020517609A (ja) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | ピロロベンゾジアゼピン複合体 |
| ES2977788T3 (es) | 2017-04-20 | 2024-08-30 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco |
| US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| EA039276B1 (ru) | 2017-08-18 | 2021-12-27 | Медимьюн Лимитед | Пирролобензодиазепиновые конъюгаты |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2019215510A2 (en) | 2018-05-09 | 2019-11-14 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| PE20210634A1 (es) * | 2018-05-24 | 2021-03-23 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| CN112867510A (zh) | 2018-10-19 | 2021-05-28 | 免疫医疗有限公司 | 吡咯并苯并二氮杂䓬缀合物 |
| JP2022512716A (ja) | 2018-10-19 | 2022-02-07 | メドイミューン・リミテッド | ピロロベンゾジアゼピン複合体 |
| JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック， インコーポレイテッド | Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
| EP3667323B1 (en) | 2018-12-11 | 2024-11-13 | AF Chemical LLC | Methods, compositions and devices for treating cancer with illudofulvenes |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| WO2020164561A1 (en) | 2019-02-15 | 2020-08-20 | Wuxi Biologics (Shanghai) Co. Ltd. | Process for preparing antibody-drug conjugates with improved homogeneity |
| KR102503143B1 (ko) * | 2019-03-06 | 2023-02-24 | 주식회사 레고켐 바이오사이언스 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| BR112021018260A2 (pt) | 2019-03-15 | 2021-11-23 | Medimmune Ltd | Dímeros de azetidobenzodiazepina e conjugados compreendendo-os para uso no tratamento de câncer |
| RS63715B1 (sr) | 2019-03-29 | 2022-11-30 | Medimmune Ltd | Jedinjenja i njihovi konjugati |
| MA55529A (fr) | 2019-04-03 | 2022-02-09 | Genzyme Corp | Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3983082A1 (en) | 2019-06-13 | 2022-04-20 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| CN114630684A (zh) | 2019-09-03 | 2022-06-14 | 博尔特生物治疗药物有限公司 | 氨基喹啉化合物、免疫缀合物及其用途 |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| MX2022003740A (es) | 2019-09-30 | 2022-05-02 | Bolt Biotherapeutics Inc | Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos. |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4048315B1 (en) | 2019-10-25 | 2025-03-12 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| WO2021080608A1 (en) | 2019-10-25 | 2021-04-29 | Medimmune, Llc | Branched moiety for use in conjugates |
| US11591295B2 (en) | 2019-11-25 | 2023-02-28 | Af Chemicals Llc | Affinity illudofulvene conjugates |
| TW202140076A (zh) | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| MX2022009052A (es) | 2020-01-22 | 2022-08-15 | Medimmune Ltd | Compuestos y conjugados de estos. |
| WO2021226440A1 (en) | 2020-05-08 | 2021-11-11 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| IL300316A (en) | 2020-08-13 | 2023-04-01 | Bolt Biotherapeutics Inc | Immune conjugates of pyrazolozapines and their uses |
| EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| CN116829592A (zh) | 2020-09-11 | 2023-09-29 | 免疫医疗有限公司 | 治疗性b7-h4结合分子 |
| KR20230118149A (ko) | 2020-12-11 | 2023-08-10 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 항-pd-l1 면역접합체, 및 그의 용도 |
| EP4259210A2 (en) | 2020-12-11 | 2023-10-18 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| EP4259211A1 (en) | 2020-12-11 | 2023-10-18 | Bolt Biotherapeutics, Inc. | Anti-her2 immunoconjugates, and uses thereof |
| US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| JP2023552792A (ja) | 2020-12-11 | 2023-12-19 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ｈｅｒ２免疫複合体、及びその使用 |
| EP4046996A1 (en) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Cryptophycin compounds and conjugates thereof |
| EP4308242A1 (en) | 2021-03-17 | 2024-01-24 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
| WO2022204528A1 (en) | 2021-03-26 | 2022-09-29 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| WO2022204536A1 (en) | 2021-03-26 | 2022-09-29 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| GB202105187D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP4323399A4 (en) | 2021-04-14 | 2025-04-09 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4422697A1 (en) | 2021-10-29 | 2024-09-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| KR20240099430A (ko) | 2021-11-10 | 2024-06-28 | 아스트라제네카 아베 | 항체 분자 및 접합체 |
| US20230285580A1 (en) | 2021-11-19 | 2023-09-14 | Adc Therapeutics Sa | Anti-il-13ralpha2 conjugates |
| US20230201366A1 (en) | 2021-11-19 | 2023-06-29 | Adc Therapeutics Sa | Anti-psma conjugates |
| CN114214341B (zh) * | 2021-12-30 | 2023-12-26 | 山西大学 | 番茄SlSERAT1;1基因或其片段在植物发育过程中的应用 |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| EP4230222A1 (en) | 2022-02-17 | 2023-08-23 | Oxsonics Limited | Combination therapy with an anti-axl antibody-pbd conjugate and nanocups |
| IL315178A (en) | 2022-02-28 | 2024-10-01 | Adc Therapeutics Sa | Dosage regimen |
| AU2023229884A1 (en) | 2022-03-09 | 2024-10-10 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
| KR20240162086A (ko) | 2022-03-11 | 2024-11-14 | 아스트라제네카 아베 | 항-FRα 항체-약물 접합체 치료법에 대한 점수 산정 방법 |
| US20250195683A1 (en) * | 2022-04-29 | 2025-06-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugate, pharmaceutical composition thereof and use therof |
| TW202417040A (zh) | 2022-06-27 | 2024-05-01 | 瑞典商阿斯特捷利康公司 | 涉及用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑之組合 |
| CA3261509A1 (en) | 2022-09-09 | 2024-03-14 | Imperial College Innovations Limited | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY |
| KR20250099224A (ko) | 2022-11-01 | 2025-07-01 | 하이델베르크 파마 리서치 게엠베하 | 항-gucy2c 항체 및 이의 용도 |
| CN121002040A (zh) | 2022-12-14 | 2025-11-21 | 费恩治疗有限公司 | 细胞毒性化合物 |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| CN120417934A (zh) | 2022-12-23 | 2025-08-01 | 基因泰克公司 | Cereblon降解剂缀合物及其用途 |
| EP4410314A1 (en) | 2023-02-02 | 2024-08-07 | ADC Therapeutics SA | Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| CN120936382A (zh) | 2023-02-16 | 2025-11-11 | 阿斯利康(瑞典)有限公司 | 采用治疗性结合分子治疗癌症的组合疗法 |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| KR20250152101A (ko) | 2023-03-13 | 2025-10-22 | 하이델베르크 파마 리서치 게엠베하 | 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체 |
| TW202506194A (zh) | 2023-04-28 | 2025-02-16 | 英商梅迪繆思有限公司 | 用於治療癌症的ｂ７－ｈ４治療性結合分子 |
| WO2025083067A1 (en) | 2023-10-17 | 2025-04-24 | Adc Therapeutics Sa | Anti-claudin-6 conjugates |
| WO2025083061A1 (en) | 2023-10-17 | 2025-04-24 | Adc Therapeutics Sa | Anti-napi2b conjugates |
| WO2025083064A1 (en) | 2023-10-17 | 2025-04-24 | Adc Therapeutics Sa | Anti-asct2 conjugates |
| EP4548936A1 (en) * | 2023-10-30 | 2025-05-07 | BioNTech SE | Antibody-drug conjugates having a tailor-made drug-to-antibody ratio |
| WO2025109097A2 (en) | 2023-11-24 | 2025-05-30 | Heidelberg Pharma Research Gmbh | Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof |
| US20250186604A1 (en) | 2023-12-06 | 2025-06-12 | Adc Therapeutics Sa | Anti-psma antibody conjugates |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| GB202403391D0 (en) | 2024-03-08 | 2024-04-24 | Myricx Pharma Ltd | Novel compounds and their use in therapy |
| GB202405758D0 (en) | 2024-04-24 | 2024-06-05 | King S College London | Compounds |
| GB202407700D0 (en) | 2024-05-30 | 2024-07-17 | Francis Crick Institute Ltd | F-actin binding agents |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5240912A (en) * | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
| ATE85080T1 (de) | 1984-02-17 | 1993-02-15 | Genentech Inc | Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5182261A (en) * | 1989-07-13 | 1993-01-26 | The Rockefeller University | Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof |
| AU4924893A (en) | 1992-09-16 | 1994-04-12 | Galagen, Inc. | Antibody treatment of (helicobacter pylori) |
| US5333033A (en) * | 1992-10-08 | 1994-07-26 | Eastman Kodak Company | Apparatus for transporting a film cartridge through a photofinishing process |
| US5635483A (en) * | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ATE282630T1 (de) * | 1993-10-01 | 2004-12-15 | Teikoku Hormone Mfg Co Ltd | Dolastatin-derivate |
| AU8116494A (en) | 1993-11-12 | 1995-06-13 | Kenichi Matsubara | Gene signature |
| US5633147A (en) * | 1994-03-08 | 1997-05-27 | Human Genome Sciences, Inc. | Transforming growth factor αH1 |
| US6410506B1 (en) * | 1995-05-19 | 2002-06-25 | Human Genome Sciences, Inc. | Transforming growth factor α HII |
| CA2230127A1 (en) * | 1995-09-18 | 1997-03-27 | Intracel Corporation | Neutralizing monoclonal antibodies to respiratory syncytial virus |
| WO1997025349A1 (en) | 1996-01-04 | 1997-07-17 | Human Genome Sciences, Inc. | Transforming growth factor alpha hiii |
| JP3646191B2 (ja) * | 1996-03-19 | 2005-05-11 | 大塚製薬株式会社 | ヒト遺伝子 |
| US20020025551A1 (en) * | 1998-04-09 | 2002-02-28 | Millennium Pharmaceuticals, Inc., A Delaware Corporation | Novel molecules of the t129-related protein family and uses thereof |
| US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US6248564B1 (en) * | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| NZ503489A (en) * | 1997-10-03 | 2002-11-26 | Chugai Pharmaceutical Co Ltd | Natural humanized antibody, method of production and pharmaceutical composition |
| WO2000012126A1 (en) * | 1998-08-26 | 2000-03-09 | The Regents Of The University Of California | Autoantibody inhibitors |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| EP1445318A2 (en) | 2000-08-24 | 2004-08-11 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) * | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
| WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| WO2003049704A2 (en) | 2001-12-11 | 2003-06-19 | University Of Massachusetts | Antibodies to treat cancer |
| DE10161625A1 (de) * | 2001-12-14 | 2003-07-10 | Epigenomics Ag | Verfahren und Nukleinsäuren für die Analyse einer Lungenzell-Zellteilungsstörung |
| US7261890B2 (en) | 2001-12-21 | 2007-08-28 | Idexx Laboratories, Inc. | Methods for using canine immunoglobulin variable domains and caninized antibodies |
| EP1340818A1 (en) * | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| SI1572087T1 (sl) * | 2002-03-08 | 2008-10-31 | Pdl Biopharma Inc | Protitelesa proti antigenu tmeff2 raka in njihovauporaba |
| US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| AU2003300504B2 (en) * | 2002-10-01 | 2009-10-01 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
| US7608429B2 (en) * | 2002-10-31 | 2009-10-27 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| US20060051359A1 (en) | 2002-12-02 | 2006-03-09 | Ira Pastan | Recombinant immunotoxin and use in treating tumors |
| EP1585768A2 (en) * | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| DK1725249T3 (en) * | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
| CA2487578A1 (en) * | 2003-12-11 | 2005-06-11 | Epigenomics Ag | Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients |
| CN114053429A (zh) * | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| ES2579805T3 (es) * | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| WO2007011896A2 (en) * | 2005-07-18 | 2007-01-25 | The Trustees Of Boston University | Method to inhibit proliferation and growth of metastases |
| DK1982178T3 (da) * | 2006-02-07 | 2013-09-08 | Phenoquest Ag | Fremgangsmåder til behandling af affektbetonede lidelser |
| US7754428B2 (en) * | 2006-05-03 | 2010-07-13 | The Chinese University Of Hong Kong | Fetal methylation markers |
| JP2009538629A (ja) | 2006-05-30 | 2009-11-12 | ジェネンテック・インコーポレーテッド | 抗体およびイムノコンジュゲートとこれらの使用方法 |
| ES2538214T3 (es) * | 2006-08-08 | 2015-06-18 | Epigenomics Ag | Un método para el análisis de metilación de ácido nucleico |
| BRPI0806403A2 (pt) * | 2007-02-09 | 2011-09-06 | Genentech Inc | anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem |
| CL2008001334A1 (es) * | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| ES2381788T3 (es) * | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| RU2557319C2 (ru) * | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| US8937161B2 (en) | 2007-10-19 | 2015-01-20 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
-
2008
- 2008-10-16 US US12/288,181 patent/US8937161B2/en not_active Expired - Fee Related
- 2008-10-16 CA CA2698541A patent/CA2698541C/en not_active Expired - Fee Related
- 2008-10-16 EP EP08839947.2A patent/EP2209808B1/en active Active
- 2008-10-16 RU RU2010119937/10A patent/RU2505544C2/ru not_active IP Right Cessation
- 2008-10-16 MY MYPI2010001746A patent/MY188455A/en unknown
- 2008-10-16 MX MX2010003718A patent/MX2010003718A/es active IP Right Grant
- 2008-10-16 CN CN200880112091.0A patent/CN101835803B/zh not_active Expired - Fee Related
- 2008-10-16 NZ NZ584514A patent/NZ584514A/en not_active IP Right Cessation
- 2008-10-16 JP JP2010530101A patent/JP5606916B2/ja not_active Expired - Fee Related
- 2008-10-16 ES ES08839947.2T patent/ES2450755T3/es active Active
- 2008-10-16 WO PCT/US2008/080102 patent/WO2009052249A1/en not_active Ceased
- 2008-10-16 KR KR1020107010851A patent/KR101622412B1/ko not_active Expired - Fee Related
- 2008-10-16 BR BRPI0818780 patent/BRPI0818780A2/pt not_active Application Discontinuation
- 2008-10-16 AU AU2008312457A patent/AU2008312457B2/en not_active Ceased
- 2008-10-17 TW TW097139977A patent/TWI438004B/zh not_active IP Right Cessation
- 2008-10-17 CL CL2008003074A patent/CL2008003074A1/es unknown
- 2008-10-17 PE PE2013002366A patent/PE20140833A1/es not_active Application Discontinuation
- 2008-10-17 PE PE2008001798A patent/PE20091112A1/es active IP Right Grant
- 2008-10-20 AR ARP080104577A patent/AR068941A1/es not_active Application Discontinuation
-
2010
- 2010-02-25 IL IL204159A patent/IL204159A/en active IP Right Grant
- 2010-02-25 ZA ZA2010/01383A patent/ZA201001383B/en unknown
- 2010-03-19 CO CO10033044A patent/CO6390071A2/es active IP Right Grant
-
2013
- 2013-04-30 JP JP2013095417A patent/JP2013173776A/ja not_active Withdrawn
-
2014
- 2014-07-10 AU AU2014203779A patent/AU2014203779A1/en not_active Abandoned
- 2014-11-24 US US14/552,244 patent/US20150158952A1/en not_active Abandoned
-
2016
- 2016-11-08 US US15/346,532 patent/US20170166635A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504460A5 (enExample) | ||
| JP2010526821A5 (enExample) | ||
| JP2011515069A5 (enExample) | ||
| RU2010119937A (ru) | Антитела против tenb2, сконструированные с цистеином, и конъюгаты антитело-лекарственное средство | |
| JP2011514146A5 (enExample) | ||
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| AU2014312215B2 (en) | Site-specific antibody conjugation methods and compositions | |
| RU2010136303A (ru) | Композиции и способы лечения опухолей гематопоэтического происхождения | |
| EP2416805B1 (en) | Amatoxin antibody conjugates for the treatment of cancer | |
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| US20070190060A1 (en) | Passive targeting of cytotoxic agents | |
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HRP20161029T1 (hr) | Protutijela anti-cd79b i imunokonjugati kao i postupci njihove uporabe | |
| JP2019532056A5 (enExample) | ||
| JP2020525542A5 (enExample) | ||
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2012522513A5 (enExample) | ||
| TW201116300A (en) | DR5 Ligand Drug Conjugates | |
| JP2012522512A5 (enExample) | ||
| AU2014312215A1 (en) | Site-specific antibody conjugation methods and compositions | |
| JP7440509B2 (ja) | Ｃｄｃｐ１－標的化療法 | |
| TW202045536A (zh) | 抗ｃｄ２２８抗體及抗體－藥物共軛體 | |
| JP2019517565A (ja) | 細胞標的化結合体 | |
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| JP2020534326A (ja) | イムノコンジュゲートにおけるメチオニン酸化を防止する方法 |